Management of Dense Calcification of the Distal Aorta

Diagnostic Workup

The European Heart Journal recommends obtaining contrast-enhanced cardiovascular computed tomography (CCT) of the entire aorta to accurately assess aortic diameter and exclude aneurysmal disease 1
If CCT is contraindicated, the European Heart Journal suggests cardiovascular magnetic resonance (CMR) as an acceptable alternative, though calcification assessment is more challenging 1
The American College of Cardiology recommends measuring the abdominal aortic diameter using outer-to-outer convention in cross-sectional view, as this method is preferred when atherosclerotic plaques are present 1

The European Heart Journal recommends elective repair if aneurysm diameter reaches ≥55 mm in men or ≥50 mm in women (Class I, Level A recommendation) 1
The European Heart Journal suggests considering repair if aneurysm growth is ≥5 mm in 6 months or ≥10 mm per year (Class IIb, Level C) 1
For patients with suitable anatomy and life expectancy >2 years, the European Heart Journal prefers endovascular aortic repair (EVAR) over open surgery, as it reduces peri-operative mortality to <1% and avoids direct manipulation of the heavily calcified aorta 1
The European Heart Journal recommends aggressive medical management, including intensive lipid-lowering therapy targeting LDL-C <55 mg/dL, for patients with dense calcification of the distal aorta 2

The European Heart Journal recommends lifelong surveillance with repeat imaging to monitor for aneurysm development or progression 1
The European Heart Journal suggests performing CCT or CMR every 3-5 years, adapted to clinical status and previous imaging findings, if aneurysm is present but below intervention thresholds 2, 3
The European Heart Journal recommends surveillance intervals of every 3-5 years unless clinical deterioration occurs if no aneurysm is present 3

The European Heart Journal recommends targeting LDL-C reduction by ≥50% from baseline AND achieving LDL-C goal of <1.4 mmol/L (<55 mg/dL) (Class I, Level A recommendation) 2
The European Heart Journal suggests statin therapy to improve survival in patients with aortic disease under medical management 4
The European Heart Journal recommends targeting systolic blood pressure toward 120-129 mmHg if tolerated (Class I, Level A recommendation) 2
The European Heart Journal suggests considering ACE inhibitors or ARBs in all patients with peripheral arterial disease, regardless of baseline blood pressure, in the absence of contraindications (Class IIb, Level B) 2

The European Heart Journal recommends full oral anticoagulation if the patient has newly diagnosed atrial fibrillation with CHA2DS2-VASc score ≥2 3
The European Heart Journal suggests considering combination therapy with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily (Class IIa, Level A) for patients with stable polyvascular disease who are symptomatic and without high bleeding risk 2